[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338327-105":3,"doc-detail-338327-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","applying-whole-genome-and-whole-exome-sequencing-in-breast-cancer-a-review-of-the-landscape","Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape","","Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are reviewed as essential tools in breast cancer research, supporting detection of predisposition genes, risk stratification, and identification of rare single nucleotide polymorphisms (SNPs). The review explains how these approaches reveal associations between genetic syndromes and breast cancer, clarify tumour microenvironment (TME) biology, and uncover novel mutations that may inform future personalised therapies. It also outlines use in early screening, diagnosis, treatment planning, prevention, and discovery of candidate genes relevant to improving patient outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/applying-whole-genome-and-whole-exome-sequencing-in-breast-cancer-a-review-of-the-landscape/338327/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/applying-whole-genome-and-whole-exome-sequencing-in-breast-cancer-a-review-of-the-landscape/338327.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do WGS and WES contribute to breast cancer research?","Question",{"text":63,"@type":64},"They help detect predisposition genes, support risk stratification, and identify rare SNPs, enabling discovery of genetic associations with breast cancer and improvements in personalised treatment concepts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What clinical applications are discussed for genetic analysis in breast cancer?",{"text":68,"@type":64},"Genetic analysis can guide early screening and diagnosis, inform specific treatment plans, and support prevention strategies for patients at high risk of tumour formation.",{"name":70,"@type":61,"acceptedAnswer":71},"What major breast cancer types and molecular subtypes are mentioned?",{"text":72,"@type":64},"The text highlights invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) as prevalent types, and describes four molecular forms (Luminal A, Luminal B, HER2+, and TNBC) based on receptor status and related markers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338327,1790194368,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0",8,"Breast Cancer (2024) 31:999–1009  \n[https://doi.org/10.1007/s12282-024-01628-9](https://doi.org/10.1007/s12282-024-01628-9)  \nApplying whole‑genome and whole‑exome sequencing in breast cancer: a review of the landscape  \nHetvi Ganatra1 · Joecelyn Kirani Tan2,3 · Ana Simmons4 · Carola Maria Bigogno5,6 · Vatsala Khurana7 · Aruni Ghose5,8,9 · Adheesh Ghosh10 · Ishika Mahajan11 · Stergios Boussios8,12,13,14,15 · Akash Maniam16,17,18 · Olubukola Ayodele19,20  \nReceived: 15 March 2024 / Accepted: 19 August 2024 / Published online: 27 August 2024 © Crown 2024  \nAbstract  \nWhole-genome sequencing (WGS) and whole-exome sequencing (WES) are crucial within the context of breast cancer (BC) research. They play a role in the detection of predisposed genes, risk stratification, and identification of rare single nucleotide polymorphisms (SNPs). These technologies aid in the discovery of associations between various syndromes and BC, understanding the tumour microenvironment (TME), and even identifying unknown mutations that could be useful in future for personalised treatments. Genetic analysis can find the associated risk of BC and can be used in early screening, diagnosis, specific treatment plans, and prevention in patients who are at high risk of tumour formation. This article focuses on the application of WES and WGS, and how uncovering novel candidate genes associated with BC can aid in treating and preventing BC.  \nKeywords Sequencing · Breast cancer · Exome · Genome · Whole-genome sequencing · Whole-exome sequencing  \nIntroduction  \nBreast cancer (BC) stands as a significant global health challenge. Prior to 2020, BC ranked as the second most prevalent cancer worldwide amongst females; however, since 2020, it has surpassed lung cancer in prevalence, marking a notable shift in disease burden [1] . In 2020 alone, 2.3 million new cases of BC were diagnosed in women, resulting in 685,000 deaths globally, rendering it the fifth leading cause of death that year [2] . Such statistics underscore the urgent need to address the burden of BC. Twenty-three percent of BC cases in the UK can be preventable [3]. Thus, emphasis on preven  \ntion as well as optimal treatment becomes paramount.  \nBC diagnosis typically involves a multifaceted approach. First, clinical breast examination (CBE) conducted by healthcare professionals entails a physical assessment of the breasts for anomalies such as lumps, changes in size or shape, or skin dimpling [4, 5] . Mammography, an X-ray imaging technique, aids in detecting suspicious masses or  \nHetvi Ganatra, Joecelyn Kirani Tan and Ana Simmons have contributed equally.  \nExtended author information available on the last page of the article  \ncalcifications in breast tissue which are otherwise not found or fully interpreted by CBE. Ultrasound, another imaging technique which utilises sound waves, offers further imaging to distinguish between solid masses and fluid-filled cysts [5, 6]. Lastly, if anything is suspected, a biopsy can be taken and thoroughly analysed in a laboratory.  \nTreatment modalities for BC encompass pharmacological, radiological, and surgical interventions. Pharmacological approaches involve chemotherapy, hormone therapy, and/ or targeted therapy [7] .  \nRadiological treatments target BC cells and surrounding lymph nodes, while surgical options include lumpectomy or mastectomy to remove tumours or the entire breast tissue [8–10] . These management options can also be utilised in combination for optimal cancer management. Wholegenome sequencing (WGS) and whole-exome sequencing (WES) have emerged as technologies capable of elucidating genetic underpinnings in diseases [11] . Understanding the genetic landscape of BC is imperative, with genetic testing identifying individuals harbouring inherited mutations such as BRCA1 and BRCA2, which substantially elevate BC risk [12] . This comprehension facilitates targeted screening and preventive measures, such as risk-reduction surgery or intensified surv","cbCaicm38IR6zM8D","https://ap.wps.com/l/cbCaicm38IR6zM8D","pdf",886404,11,"English","# Abstract\n# Introduction\n## Breast cancer burden and prevention emphasis\n## Diagnostic and treatment landscape\n# Breast cancer classification\n## Common histological types\n## Molecular subtypes","[{\"question\":\"How do WGS and WES contribute to breast cancer research?\",\"answer\":\"They help detect predisposition genes, support risk stratification, and identify rare SNPs, enabling discovery of genetic associations with breast cancer and improvements in personalised treatment concepts.\"},{\"question\":\"What clinical applications are discussed for genetic analysis in breast cancer?\",\"answer\":\"Genetic analysis can guide early screening and diagnosis, inform specific treatment plans, and support prevention strategies for patients at high risk of tumour formation.\"},{\"question\":\"What major breast cancer types and molecular subtypes are mentioned?\",\"answer\":\"The text highlights invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) as prevalent types, and describes four molecular forms (Luminal A, Luminal B, HER2+, and TNBC) based on receptor status and related markers.\"}]","Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape | PDF",1790023081,28,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2876297e4be2be2de771a94133eab256.webp",983,1305,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c1efc3fc79b5ea8fd1cb373ce8bf485.webp",982,1304,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f169738004449c8b17c4e9f2f3b8b4e8.webp",981,1303,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/708413d2cbabe90262753b5b25858b78.webp",980,1301,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]